Abstract: The invention relates to compounds which contain an antigen binding region which is bound to at least one enzyme which is able to metabolize a compound (prodrug) which has little or no cytotoxicity to a cytotoxic compound (drug), where the antigen binding region is composed of a single polypeptide chain. It is advantageous for covalently bonded carbohydrates to be present on the polypeptide chain.

Abstract: Prolongation of the expression of transgenic proteins by immunomodulating treatment The invention relates to the use of one or more immunosuppressants for the production of a pharmaceutical for increasing the tolerance of a mammal to transgenic cells, and to a process for identifying immunosuppressants suitable for this. By the use of pharmaceuticals of this type, the production of the transgenic expression product is markedly prolonged even after discontinuing the immunosuppressant treatment.

Abstract: Antigenic constructs which result from linkage of major histocompatibility complex (MHC) class I antigens with specific carrier molecules are described. The linkage is effected N- or C-terminally by covalent bonding or, in the case of non-covalent bonding, for example by an avidin/biotin bridge.

Abstract: Antigenic constructs which result from linkage of major histocompatibility complex (MHC) class I antigens with specific carrier molecules are described. The linkage is effected N- or C-terminally by covalent bonding or, for example, in the case of non-covalent bonding by an avidin/biotin bridge. The specific carrier molecules bind selectively to target cells and are preferably monoclonal antibodies. Processes of genetic manipulation for the preparation of such constructs are indicated. Antigenic constructs according to the invention are used to damage or eliminate target cells.